LOE stands for Loss of Exclusivity, the point at which a brand-name drug loses the legal protections that prevent competitors from selling cheaper versions. It’s one of the most consequential events in the pharmaceutical industry, routinely wiping out 80% of a drug’s revenue within the first year. For drugmakers, LOE is the ticking clock behind nearly every business decision. For patients and health systems, it’s the moment prices finally drop.
How Exclusivity Works
When a company develops a new drug, it receives two overlapping forms of protection: patents and regulatory exclusivity. Patents are property rights granted by the patent office and can cover the drug’s chemical structure, manufacturing process, formulation, dosage form, or even its packaging. Regulatory exclusivity is different. It’s a set of delays built into the approval process that prevent the FDA (or its equivalents in other countries) from approving competitor versions for a defined period, regardless of patent status. These two protections often run at the same time, but they don’t have to. A drug could lose its patents but still have regulatory exclusivity, or vice versa.
LOE occurs when both forms of protection have expired or been successfully challenged, opening the door for generic drugs or biosimilars to enter the market.
Types of Exclusivity in the US
The US system offers several types of regulatory exclusivity, each with its own timeline. A new chemical entity, meaning a drug with an active ingredient never before approved by the FDA, receives five years of exclusivity. Orphan drugs developed for rare diseases get seven years. Clinical investigation exclusivity, granted when a company conducts new clinical trials for an already-approved drug, provides three years. Pediatric exclusivity adds six months to whatever other exclusivity or patent protection a drug already has, rewarding companies that study their drug in children.
There’s also a 180-day exclusivity window for the first generic company that challenges a brand-name drug’s patents. Under US law, the first generic applicant to file what’s called a Paragraph IV certification, essentially arguing that the brand’s patent is invalid or won’t be infringed, earns the right to be the only generic on the market for six months. During that window, the FDA cannot approve any other generic versions, even if they’re ready. This creates a powerful incentive for generic companies to take the legal risk of challenging patents early.
How the EU Differs
The European system takes a different approach. Standard drugs receive eight years of data exclusivity, during which no competitor can reference the original company’s clinical trial data to support their own application. After that, there’s a two-year period of market protection where a generic can be approved but not yet sold. Companies can earn an additional year by securing approval for a new therapeutic indication with significant clinical benefit during the initial eight-year window, creating what’s known as the “8+2+1” structure. Orphan drugs in the EU receive 10 years of market exclusivity, with a possible two-year extension for completing pediatric studies. In both the US and EU, the underlying patent term is 20 years.
The Financial Impact of LOE
The revenue consequences of LOE are severe. Generic drugs sell at a fraction of the original brand price, and brand-name drugs can lose roughly 80% of their revenue in the first year after generics arrive. The effect compounds quickly: once multiple generics enter the market, price competition among them drives costs down even further.
The pharmaceutical industry is heading into its largest patent cliff in history. Between 2025 and 2030, more than $300 billion in prescription drug revenue will lose patent protection, roughly one-sixth of the industry’s total annual revenue. Nearly 200 drugs are affected, including about 70 blockbusters that each generate over $1 billion per year. Five of the top 10 pharmaceutical companies face exposure on more than half their revenue. For context, the previous major patent cliff in 2016 eroded about $100 billion in brand-name sales. The current one is three times that size.
Humira as a Case Study
Humira, used to treat autoimmune conditions like rheumatoid arthritis and Crohn’s disease, illustrates how LOE plays out in practice. In 2021, it became the first drug ever to surpass $20 billion in global revenue, with $17.3 billion coming from US sales alone. Its manufacturer, AbbVie, had already been experiencing the effects of biosimilar competition outside the US, where international revenues dropped nearly 13% compared to the prior year.
Through a series of legal settlements with biosimilar manufacturers, AbbVie delayed US competition for years. But in 2023, at least eight biosimilar versions of Humira finally entered the US market. The pattern is typical: brand companies use every available legal and regulatory tool to extend their window, but LOE eventually arrives, and when it does, the revenue decline is steep.
How Companies Try to Delay LOE
Pharmaceutical companies use a range of strategies to push back the LOE date or soften its impact. The most common is secondary patenting, sometimes called “evergreening.” Rather than relying solely on the original patent covering the active ingredient, companies file additional patents on new formulations, dosing schedules, delivery methods, or even packaging. Some of the best-selling drugs are protected by more than a hundred patents layered on top of one another.
Another approach is launching an authorized generic: the brand-name company produces its own generic version to compete directly with independent generic entrants. This lowers the expected profits for other generic manufacturers and can deter or delay their entry into the market. Research confirms that authorized generics do succeed in reducing the number of competitors that follow.
Pay-for-delay settlements represent a more controversial tactic. In these arrangements, the brand-name company pays potential generic competitors to hold off on entering the market, effectively buying more time at monopoly prices. Regulatory authorities in both the US and EU have scrutinized these deals closely.
Companies also pursue what’s known as product hopping: introducing a slightly modified version of the drug, such as switching from a tablet to an extended-release capsule, and shifting patients to the new version before the old one loses exclusivity. If the original formulation is withdrawn or deprioritized, generic companies may find that their approved generic has a shrinking patient base.
Why LOE Shapes the Entire Industry
LOE isn’t just a financial event for individual drugs. It drives how the entire pharmaceutical industry allocates resources. Companies plan their research pipelines years in advance around projected LOE dates, aiming to have new products ready to replace lost revenue. Mergers and acquisitions frequently target companies with drugs that still have long exclusivity runways. The global generic drug market generated $74 billion in 2020 alone, reflecting the enormous commercial opportunity that LOE creates on the other side of the equation.
For health systems and patients, LOE is the primary mechanism through which drug prices eventually come down. The tension between the industry’s need to recoup development costs during the exclusivity window and the public’s need for affordable medicines after that window closes sits at the center of nearly every pharmaceutical policy debate.